Warning Spectrum Pharmaceuticals, Inc. (SPPI) optimists! Thomas Riga just Sold 3,290 shares.; Last Week INSCAPE (TSE:INQ) Analysts

May 16, 2018 - By Danny Collins

INSCAPE Corporation (TSE:INQ) Logo

Among 3 analysts covering Inscape Corp (TSE:INQ), 1 have Buy rating, 1 Sell and 1 Hold. Therefore 33% are positive. Inscape Corp had 3 analyst reports since April 3, 2017 according to SRatingsIntel. Goldman Sachs maintained the shares of INQ in report on Wednesday, April 19 with “Neutral” rating. The firm has “Buy” rating given on Monday, April 3 by Macquarie Research. See INSCAPE Corporation (TSE:INQ) latest ratings:

Inscape Corporation, together with its subsidiaries, makes office furniture and wall products in the United States, Canada, and internationally. The company has market cap of $27.32 million. The firm operates in two divisions, The Office Furniture and The Inscape Walls. It currently has negative earnings. The Office Furniture segment offers storage, benching, systems, seating solutions, and West Elm Workspace products.

It closed at $1.9 lastly. It is down 0.00% since May 16, 2017 and is . It has underperformed by 11.55% the S&P500.

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company has market cap of $1.84 billion. The firm markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-Hodgkin??s lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It currently has negative earnings. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer.

More important recent Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) news were published by: Seekingalpha.com which released: “Spectrum Pharmaceuticals’ (SPPI) CEO Joe Turgeon on Q1 2018 Results – Earnings Call Transcript” on May 03, 2018, also Ocbj.com published article titled: “Midday Stock Roundup”, Nasdaq.com published: “Can These Top-Performing Biotech Stocks Keep Climbing?” on April 30, 2018. More interesting news about Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) was released by: Seekingalpha.com and their article: “Spectrum Pharmaceuticals: What To Expect From This Powerful Grower” with publication date: April 18, 2018.

The stock increased 2.00% or $0.35 during the last trading session, reaching $17.88. About 625,644 shares traded. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) has risen 143.80% since May 16, 2017 and is uptrending. It has outperformed by 132.25% the S&P500.

Among 6 analysts covering Spectrum Pharma (NASDAQ:SPPI), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Spectrum Pharma has $3300 highest and $8.25 lowest target. $22.18’s average target is 24.05% above currents $17.88 stock price. Spectrum Pharma had 14 analyst reports since August 7, 2015 according to SRatingsIntel. FBR Capital maintained Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) on Tuesday, April 10 with “Buy” rating. The firm has “Buy” rating given on Wednesday, August 16 by H.C. Wainwright. The rating was maintained by Jefferies with “Buy” on Monday, October 9. The firm earned “Buy” rating on Friday, May 4 by H.C. Wainwright. The stock of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) has “Buy” rating given on Friday, February 10 by Jefferies. The firm earned “Buy” rating on Monday, May 14 by FBR Capital. The firm earned “Buy” rating on Wednesday, June 7 by Jefferies. The stock has “Outperform” rating by RBC Capital Markets on Thursday, November 5. As per Thursday, August 24, the company rating was maintained by Jefferies. The rating was upgraded by Zacks on Thursday, August 27 to “Hold”.

Thomas Riga; that is an insider in Spectrum Pharmaceuticals Inc who is the latest to unload shares in the company for which he is for the time being a EVP – COO & CCO. Thomas not a long ago unloaded 3,290 shares of the company, priced at approx $59,552 U.S. Dollars, that is a share price of approximately $18.1. He also sold 5,740 shares with a total value of about $107,603 USD in the last 30 days. This transaction decreased his ownership of the Company to 0.24% market cap or 247,555 shares. Dated 14-05-2018 the trade Form 4 is freely available for public review here.

Since March 21, 2018, it had 0 buys, and 21 selling transactions for $16.52 million activity. $71,123 worth of stock was sold by GUSTAFSON KURT A on Wednesday, March 28. 3,100 Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) shares with value of $56,327 were sold by Turgeon Joseph W. SHROTRIYA RAJESH C MD had sold 90,000 shares worth $1.45M on Monday, May 7. Riga Thomas J sold 5,740 shares worth $107,603. 4,200 shares were sold by Krassner Stuart Mitchell, worth $78,278.

Analysts await Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) to report earnings on August, 2. They expect $-0.23 EPS, up 11.54% or $0.03 from last year’s $-0.26 per share. After $-0.19 actual EPS reported by Spectrum Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 21.05% negative EPS growth.

Investors sentiment decreased to 1.63 in Q4 2017. Its down 1.21, from 2.84 in 2017Q3. It turned negative, as 26 investors sold Spectrum Pharmaceuticals, Inc. shares while 28 reduced holdings. 27 funds opened positions while 61 raised stakes. 78.22 million shares or 9.25% more from 71.60 million shares in 2017Q3 were reported. Pillar Pacific Capital Management Lc owns 18,500 shares. Moreover, Ameriprise Fincl has 0% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 463,756 shares. Invesco Limited holds 738,472 shares. Hap Trading Limited Liability Company stated it has 31,733 shares or 0.03% of all its holdings. New York State Common Retirement Fund stated it has 0% of its portfolio in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). 200 were reported by Vantage Invest Advsrs Ltd Liability. 39,000 are held by Louisiana State Employees Retirement System. Piermont Cap Mngmt reported 0.55% of its portfolio in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). First Quadrant L P Ca holds 0% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) or 9,192 shares. Legal And General Gru Public Limited Co invested 0% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Morgan Stanley holds 0% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) or 242,128 shares. Voya Investment Management Llc stated it has 64,564 shares or 0% of all its holdings. Serv Automobile Association invested in 0% or 29,431 shares. Manufacturers Life Ins The has 66,341 shares for 0% of their portfolio. Proshare Advisors Ltd Limited Liability Company holds 0.01% of its portfolio in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 69,884 shares.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Institutional Positions Chart